Immunomedics, Inc. (IMMU) Reports That UCB Group (UCBJF.PK) Announces New Results From Phase 2B Open-Label Extension Study Evaluating the Long-Term Effects of Epratuzumab in SLE
6/13/2013 8:49:32 AM
More...
|
UCB Group (UCBJF.PK) Chooses Emerson Automation and Operations Management Technologies for One of Europe’s Largest Biotech Plants
1/9/2013 10:12:20 AM
More...
|
UCB Group (UCBJF.PK) Announces Data on Cimzia® (certolizumab pegol) for Patients With Moderate to Severe Rheumatoid Arthritis at American College of Rheumatology 2012 Congress
11/13/2012 10:55:38 AM
More...
|
UCB Group (UCBJF.PK) Release: RAPID™ -axSpA Study Showed Certolizumab Pegol Reduced Signs and Symptoms of Axial Spondyloarthritis
11/13/2012 10:05:06 AM
More...
|
New Data From UCB Group (UCBJF.PK)'s Immunology Portfolio Highlighted at 2012 American College of Rheumatology Meeting
11/12/2012 8:53:15 AM
More...
|
UCB Group (UCBJF.PK) Release: New Post-Hoc Analyses Examined Neupro® Effects on Pain, Depressed Mood, Apathy and Fatigue in Patients with Parkinson’s Disease
4/26/2012 10:57:55 AM
More...
|
UCB Group (UCBJF.PK) Release: First Assessment of Individual RLS Domains in New Post-Hoc Analyses of Neupro® Studies
4/25/2012 10:54:26 AM
More...
|
Otsuka Pharmaceutical Co., Ltd. and UCB Group (UCBJF.PK) End Cimzia Collaboration, to Focus on CNS Disorders Instead
1/13/2012 7:59:58 AM
More...
|
UCB Group (UCBJF.PK) and Immunomedics, Inc. (IMMU) Release: Epratuzumab Phase IIB Data Demonstrated Sensitivity of BICLA, a Novel BILAG-Based Composite Endpoint
11/8/2011 11:02:49 AM
More...
|
UCB Group (UCBJF.PK) New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 Was Predictive of Week 52 Response
11/7/2011 7:26:17 AM
More...
|
|